Taysha Gene Therapies (TSHA) Asset Writedowns and Impairment (2023 - 2024)
Taysha Gene Therapies (TSHA) posted Asset Writedowns and Impairment of $4.8 million for Q3 2024, up 977.51% sequentially from $449000.0 in Q4 2023, and up 685.39% YoY from $616000.0 in Q4 2023.
Powered by 
Analysis
Taysha Gene Therapies (TSHA) Asset Writedowns and Impairment (2023 - 2024) Analysis & Trends
Taysha Gene Therapies has reported Asset Writedowns and Impairment for 2 years, with the latest figure at $4.8 million in Q3 2024.
- Quarterly Asset Writedowns and Impairment rose 685.39% year-over-year to $4.8 million in Q3 2024, while the trailing twelve-month figure through Dec 2025 was $4.8 million (down 18.04% YoY) and the FY2024 annual result came in at $4.8 million, up 354.27% from the prior year.
- Asset Writedowns and Impairment improved to $4.8 million in Q3 2024 per TSHA's latest filing, from $449000.0 in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $4.8 million in Q3 2024 and troughed at $449000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Taysha Gene Therapies | 2.06 Bn | 2.06 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 4.84 Mn |
| Dec 31, 2023 | 449,000.00 |
| Sep 30, 2023 | 616,000.00 |